FGFR4 and hepatocellular carcinoma: Ji et al. found that the miR-486-3p gene expression levels were downregulated in tumor tissues than in normal tissues in patients with hepatocellular carcinoma, and that it mediated sorafenib resistance by targeting the fibroblast growth factor receptor 4 and epidermal growth factor receptor40.